C-peptide and chronic complications in patients with type-2 diabetes and the metabolic syndrome

Presse Medicale

Volumn 38, Issue 10, 2009, Pages 1399-1403

  Mavrakanas, Thomas ^a,b   Frachebois, Claire ^a   Soualah, Arezki ^a   Aloui, Fadhela ^a   Julier, Ingrid ^a   Bastide, Dominique ^a  

^a Ales Hospital   (France)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; C REACTIVE PROTEIN; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; FEMALE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PROTEIN BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-PEPTIDE; C-REACTIVE PROTEIN; CONFIDENCE INTERVALS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE;

EID: 70349513615     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2009.02.023     Document Type: Article

References (17)

1. Steiner D.F., Clark J.L., Nolan C., Rubenstein A.H., Margoliash E., Aten B., et al. Proinsulin and the biosynthesis of insulin. Recent Prog Horm Res 25 (1969) 207-282
2. Chevenne D., Trivin F., and Porquet D. Insulin assays and reference values. Diabetes Metab 25 (1999) 459-476
3. Polonsky KS. Lilly lecture 1994. The (β-cell in diabetes: from molecular genetics to clinical research. Diabetes 1995; 44:705-17.
4. Bo S., Cavallo-Perin P., Gentile L., Repetti E., and Pagano G. Relationship of residual beta-cell function, metabolic control and chronic complications in type 2 diabetes mellitus. Acta Diabetol 37 (2000) 125-129
5. Inukai T., Matsutomo R., Tayama K., Aso Y., and Takemura Y. Relation between the serum level of C-peptide and risk factors for coronary heart disease and diabetic microangiopathy in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 107 (1999) 40-45
6. Shin S.J., Lee Y.J., Hsaio P.J., Chen J.H., Guh J.Y., Chen M.T., et al. Relationship between beta-cell function and diabetic duration and albuminuria in type 2 diabetes mellitus. Pancreas 14 (1997) 192-198
7. Göttsater A., Kangro M., and Sundkvist G. Early parasympathetic neuropathy associated with elevated fasting plasma C-peptide concentrations and late parasympathetic neuropathy with hyperglycaemia and other microvascular complications. Diabet Med 21 (2004) 1304-1309
8. Sari R., and Balci M.K. Relationship between C peptide and chronic complications in type-2 diabetes mellitus. J Natl Med Assoc 97 (2005) 1113-1118
9. Haupt E., Benecke A., Haupt A., Herrmann R., Vogel H., and Walter C. The KID Study VI: diabetic complications and associated diseases in younger type 2 diabetics still performing a profession. Prevalence and correlation with duration of diabetic state, BMI and C-peptide. Exp Clin Endocrinol Diabetes 107 (1999) 435-441
10. Boz M., Scheen A.J., Gerard P.L., Castillo M.J., and Lefebvre P.J. Retinopathy, but not neuropathy, is influenced by the level of residual endogenous insulin secretion in type 2 diabetes. Diabetes Metab 21 (1995) 353-359
11. Relimpio F., Losada F., Pumar A., Garcia de Pasquera F., Morales F., Acosta D., et al. Relationship of C-peptide levels and C-peptide/blood sugar ratio with clinical/ biochemical variables associated with insulin resistance in orally-treated, well controlled type 2 diabetic patients. Diabetes Res Clin Pract 36 (1997) 173-180
12. Bo S., Cavallo-Perin P., Gentile L., Repetti E., and Pagano G. Low HDL-cholesterol: a component of the metabolic syndrome only in the presence of fasting hypertriglyceridemia in type 2 diabetic patients. Diabetes Metab 27 (2001) 31-35
13. Haban P., Simoncic R., Zidekova E., and Ozdin L. Role of fasting serum C-peptide as a predictor of cardiovascular risk associated with the metabolic X-syndrome. Med Sci Monit 8 (2002) CR175-CR179
14. Aoki Y. Variation of endogenous insulin secretion in association with treatment status: assessment by serum C-peptide and modified urinary C-peptide. Diabetes Res Clin Pract 14 (1991) 165-173
15. Altman D.G. Practical statistics for medical research (1990), Chapman & Hall/CRC pp. 179-241
16. Abou-Raya A., Abou-Raya S., and Inflammation:. A pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 5 (2006) 331-337
17. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.